Nicotinamide is a potent inhibitor of proinflammatory cytokines

Clinical and Experimental Immunology

Volumn 131, Issue 1, 2003, Pages 48-52

  Ungerstedt, Johanna S ^a,b   Blomback M ^a   Soderstrom T ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Endotoxin; Inflammation; Nicotinamide; Poly(ADPribose)polymerase; Sepsis

Indexed keywords

6(5H) PHENANTHRIDINONE; CYTOKINE; ENDOTOXIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; ENDOTOXEMIA; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; INHIBITION KINETICS; MALE; PRIORITY JOURNAL; STIMULATION;

ADJUVANTS, IMMUNOLOGIC; CELLS, CULTURED; CYTOKINES; DEPRESSION, CHEMICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXEMIA; ENZYME INHIBITORS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; INTERLEUKIN-8; NIACINAMIDE; PHENANTHRENES; POLY ADENOSINE DIPHOSPHATE RIBOSE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037232298     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02031.x     Document Type: Article

References (40)

1. Schumann RR, Latz E. Lipopolysaccharide-binding protein. Chem Immunol 2000;74:42-60.
2. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431-3.
3. Verbon A, Dekkers PE, ten Hove T et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001;166:3599-605.
4. Muller JM, Ziegler-Heitbrock HWL, Bauerle PA. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology 1993;187:233-56.
5. Fong Y, Lowry SF. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol 1990;55:157-70.
6. Martich GD, Boujoukos AJ, Suffredini AF. Response of man to endotoxin. Immunobiology 1993;187:403-16.
7. Gardlund B, Sjolin J, Nilsson A, Roll M, Wickerts CJ, Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 1995;172:296-301.
8. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1:355-7.
9. Roumen RM, Hendriks T, van der Ven-Jongekrijg J, Nieuwenhuijzen GA, Sauerwein RW, van der Meer JW, Goris RJ. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993;218:769-76.
10. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993;103:565-75.
11. Andersen HU, Jorgensen KH, Egeberg J, Mandrup-Poulsen T, Nerup J. Nicotinamide prevents interleukin-1 effects on accumulated insulin release and nitric oxide production in rat islets of Langerhans. Diabetes 1994;43:770-7.
12. Burkart V, Koike T, Brenner HH, Kolb H. Oxygen radicals generated by the enzyme xanthine oxidase lyse rat pancreatic islet cells in vitro. Diabetologia 1992;35:1028-34.
13. Otsuka A, Hanafusa T, Miyagawa J, Kono N, Tarui S. Nicotinamide and 3-aminobenzamide reduce interferon-gamma-induced class II MHC (HLA-DR and -DP) molecule expression on cultured human endothelial cells and fibroblasts. Immunopharmacol Immunotoxicol 1991;13:263-80.
14. Hiromatsu Y, Sato M, Tanaka K, Ishisaka N, Kamachi J, Nonaka K. Inhibitory effects of nicotinamide on intercellular adhesion molecule-1 expression on cultured human thyroid cells. Immunology 1993;80:330-2.
15. Pero RW, Axelsson B, Siemann D, Chaplin D, Dougherty G. Newly discovered anti-inflammatory properties of the benzamides and nicotinamides. Mol Cell Biochem 1999;193:119-25.
16. Szabo C. Cell death: the role of PARP. Boca Raton: CRC Press, 2000.
17. DeMurcia G, Shall S. From DNA Damage and Stress Signaling to Cell Death; Poly ADP-Ribosylation Reactions. Oxford: Oxford University Press, 2000.
18. Green RG. Subclinical pellagra. its diagnosis and treatment. Schizophrenia 1970;2:70-9.
19. Hawkins DR. Treatment of schizophrenia based on the medical model. J Schizophr 1968;2:3-10.
20. Vague P, Picq R, Bernal M, Lassmann-Vague V, Vialettes B. Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients. Diabetologia 1989;32:316-21.
21. Zackheim HS. Topical 6-aminonicotinamide plus oral niacinamide therapy for psoriasis. Arch Dermatol 1978;114:1632-8.
22. Weltin D, Picard V, Aupeix K, Varin M, Oth D, Marchal J, Dufour P, Bischoff P. Immunosuppressive activities of 6(5H)-phenanthridinone, a new poly (ADP-ribose) polymerase inhibitor. Int J Immunopharmacol 1995;17:265-71.
23. Hartree EF. Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem 1972;48:422-7.
24. Babson AL, Olson DR, Palmieri T, Ross AF, Becker DM, Mulqueen PJ. The IMMULITE assay tube: a new approach to heterogeneous ligand assay. Clin Chem 1991;37:1521-2.
25. Fukuzawa M, Satoh J, Muto G, Muto Y, Nishimura S, Miyaguchi S, Qiang XL, Toyota T. Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-alpha. Immunol Lett 1997;59:7-11.
26. van der Poll T, Levi M, Hack CE et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994;179:1253-9.
27. Ashkenazi A, Marsters SA, Capon DJ et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 1991;88:10535-9.
28. Emerson TE Jr, Lindsey DC, Jesmok GJ, Duerr ML, Fournel MA. Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model. Circ Shock 1992;38:75-84.
29. Calandra T, Baumgartner JD, Glauser MP. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock. Prog Clin Biol Res 1991;367:141-59.
30. Liaudet L, Pacher P, Mabley JG, Virag L, Soriano FG, Hasko G, Szabo C. Activation of poly (ADP-Ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am J Respir Crit Care Med 2002;165:372-7.
31. Kuhnle S, Nicotera P, Wendel A, Leist M. Prevention of endotoxin-induced lethality, but not of liver apoptosis in poly (ADP-ribose) polymerase-deficient mice. Biochem Biophys Res Commun 1999;263:433-8.
32. Szabo C, Wong HR, Bauer PI et al. Regulation of components of the inflammatory response by 5-iodo-6-amino-1,2-benzopyrone, an inhibitor of poly (ADP-ribose) synthetase and pleiotropic modifier of cellular signal pathways. Int J Oncol 1997;10:1093-101.
33. Szabo C, Zingarelli B, Salzman AL. Role of poly-ADP ribosyltransferase activation in the vascular contractile and energetic failure elicited by exogenous and endogenous nitric oxide and peroxynitrite. Circ Res 1996;78:1051-63.
34. Jagtap P, Soriano FG, Virag L et al. Novel phenanthridinone inhibitors of poly (adenosine 5′-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med 2002;30:1071-82.
35. Mabley JG, Jagtap P, Perretti M et al. Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase. Inflamm Res 2001;50:561-9.
36. Hassa PO, Hottiger MO. A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. Biol Chem 1999;380:953-9.
37. Oliver FJ, Menissier-de Murcia J, Nacci C et al. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. Embo J 1999;18:4446-54.
38. Horwitt MK. Niacin-tryptophan relationships in the development of pellagra. Am J Nutrition 1955;3:244.
39. Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA. Safety of high-dose nicotinamide: a review. Diabetologia 2000;43:1337-45.
40. Zackheim HS. Reactions to nicotinamide. J Am Assoc Dermol 1981;4:736-7.